Cumberland Pharmaceuticals (CPIX) Cost of Revenue (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Cost of Revenue across 17 years of filings, most recently posting $1.9 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $1.9 million, down 54.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 105.13% YoY), and the FY2025 annual result was $6.7 million, up 1.23% from the prior year.
• Cost of Revenue came in at $1.9 million for Q1 2026 at Cumberland Pharmaceuticals, up from -$6.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $10.2 million in Q4 2022 to a low of -$6.2 million in Q4 2025.
• The 5-year median for Cost of Revenue is $2.2 million (2022), against an average of $2.4 million.
• Across the five-year window, Cost of Revenue tumbled 506.18% in 2024 and jumped 235.13% in 2025, its largest moves.
• Cumberland Pharmaceuticals' Cost of Revenue stood at $10.2 million in 2022, then slumped by 84.99% to $1.5 million in 2023, then sank by 506.18% to -$6.2 million in 2024, then slipped by 0.12% to -$6.2 million in 2025, then jumped by 131.08% to $1.9 million in 2026.
• The last three Cost of Revenue figures came in at $1.9 million (Q1 2026), -$6.2 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.